NaijWeb Keeping you informed…
Danish drugmaker Bavarian Nordic announced on Friday that it is seeking European approval to use its mpox vaccine in children aged 12 to 17.
This comes after the World Health Organization (WHO) declared the rapid spread of the new, more dangerous pox strain, Clade 1b, a public health emergency of international concern.
Bavarian Nordic’s vaccine is currently approved for people 18 and older, but the company highlights the urgency of broadening vaccine access for children and adolescents, who are disproportionately affected by the outbreak in Africa.
As cases of the new pox strain have been reported in Sweden and Pakistan this week, the WHO warns of further imported cases in Europe.
Read Also: Monkey Pox Symptoms, How to avoid monkeypox in Nigeria
Bavarian Nordic has stated that it is prepared to produce 10 million vaccine doses by 2025 but is currently waiting for countries to place orders.
Meanwhile, it is essential for people to remain vigilant and conscious of their everyday activities, noting any symptoms until the vaccines are made available to younger age groups.
